Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia

Documenti analoghi

• Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide
  di: Stölzel, Friedrich, et al.
  Pubblicazione: (2010)
• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
  di: Sockel, Katja, et al.
  Pubblicazione: (2011)
• Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
  di: Schönefeldt, C, et al.
  Pubblicazione: (2013)
• Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring
  di: Oelschlaegel, Uta, et al.
  Pubblicazione: (2015)
• Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial
  di: Sockel, Katja, et al.
  Pubblicazione: (2012)